Nova Leap Health (NLH) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenues reached $7,851,894, up 10.7% year-over-year from Q1 2025.

• Trailing twelve-month revenues hit a record $32,225,075 for the period ending March 31, 2026.

• Adjusted EBITDA for Q1 2026 was $461,308, a 59.6% increase over Q1 2025.

• Net income for Q1 2026 was $324,587, reversing a net loss of $78,299 in Q1 2025.

• The company completed a strategic acquisition in Nova Scotia after quarter-end, enhancing scale and profitability.

Financial highlights

• Gross profit margin was 39.9% in Q1 2026, up from 39.0% in Q1 2025.

• Operating income for Q1 2026 was $291,242, up $216,090 from Q1 2025.

• Available cash as of March 31, 2026 was $1,605,102, with full access to a $1,076,117 revolving credit facility.

• Total demand loans and promissory notes outstanding were $1,962,421, with a leverage ratio of 0.88x trailing twelve-month Adjusted EBITDA.

Outlook and guidance

• Management expects continued growth and improved profitability as operating leverage increases.

• Expansion of care management and palliative care initiatives is underway, with a long-term growth focus.

• Over $3 million in available credit supports ongoing acquisition strategy.